Recent investigations in peritoneal mesothelioma have suggested that BAP1 haploinsufficiency is correlated with an inflammatory tumor microenvironment and may be a potential prognostic and predictive biomarker for immunotherapy [53]. The gene discussed is BAP1; the disease is peritoneal mesothelioma.